Trilaciclib

Org: Los Angeles Cancer Network, Inova Schar Cancer Institute, Northwest Medical Specialties, Virginia Oncology Associates, Valkyrie Clinical Trials, Inc,

Abstract

Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials.

Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, M Abdur Rahim Medical College, JCCR,

Clinical trial

ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

A Phase II Clinical Study of Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Status: Not yet recruiting, Estimated PCD: 2025-02-01

Clinical trial

A Prospective, Multi-cohort, Exploratory Phase II Study of Trilaciclib Combined With Standard Chemotherapy in The Adjuvant Treatment of Hormone Receptor (HR) Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A Phase II, Randomized, Open-label Trial of Trilaciclib Prior to Chemotherapy Plus Tislelizumab as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2024-10-31

Clinical trial

Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-07-25

Clinical trial

A Single Arm, Exploratory Clinical Study on the Prevention of Bone Marrow Suppression Caused by Platinum Containing Chemotherapy in Advanced Non-small Cell Lung Cancer With Trilaciclib

Status: Not yet recruiting, Estimated PCD: 2025-04-30

Abstract

Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.

Org: Department of Medicine, Duke University School of Medicine, Texas Oncology-Baylor Charles A. Sammons Cancer Center, PIH Health Whittier Hospital, Nebraska Hematology-Oncology P.C., Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center,

Abstract

Real world outcomes of trilaciclib in ES-SCLC.

Org: Roswell Park Comprehensive Cancer Center, University at Buffalo School of Pharmacy and Pharmaceutical Sciences,

Clinical trial

To Evaluate the Protective Effect of Trilaciclib on Myelosuppression in Patients With Limited-stage Small Cell Lung Cancer Associated With Concurrent Chemoradiotherapy and Discuss the Effect of Gut Microbiota Changes on Myelosuppression

Status: , Estimated PCD: 2026-01-30